GSK’s Proposal For Mouth Spray Nicorette Delayed By FDA Questions On Label

Glaxo plans to make changes FDA requested in Complete Response letter sent on 18 October, the agency’s deadline for acting on NDA for an oral spray that delivers 1 mg per spray of aqueous buffered nicotine solution for oromucosal use.